Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Researchers from the Nuffield Department of Primary Care Health Sciences, University of Oxford, have today announced that they have been awarded funding through the National Institute for Health Research (NIHR) to work with several UK universities and carry out a first-of-its-kind clinical trial, testing novel antiviral COVID-19 treatments for use early on in the illness by people in the community with COVID-19 who are at higher risk of complications.

*** Recruitment now open: visit ***

The Platform Adaptive trial of NOvel antiviRals for eArly treatMent of COVID-19 In the Community (PANORAMIC) is a national priority trial, and as soon as it is set up for delivery - will be open to eligible participants from across the UK.

PANORAMIC has been designed as a ‘platform clinical trial’, meaning it can rapidly evaluate several antiviral treatments over time that could help people at high risk of COVID-19 recover sooner, prevent the need for hospital admission and so ease the burden on the NHS.

The trial’s Chief Investigator, Professor Chris Butler, Professor of Primary Care in the Nuffield Department of Primary Care Health Sciences, said:

‘It is early on in the illness, when people are still being cared for in the community, that treatments for COVID-19 could have their greatest benefit. So far, a lot of the research has focussed on finding out if well-known drugs can be repurposed to treat COVID-19.  This new trial will test whether exciting, new antiviral treatments that are more specific to COVID-19 help people in the community recover faster and reduce the need for treatment in hospital.’

The PANORAMIC trial platform is essential to enabling early and rapid testing of novel antiviral agents, given the limited success to date of trials that have explored repurposing existing drugs against COVID-19.
- Professor Richard Hobbs CBE, Head of Department, Nuffield Professor of Primary Care Health Sciences, and Co-Chief Investigator

Professor Paul Little from the University of Southampton and Co-Chief Investigator, said:

‘This trial will be one of the most ambitious ever undertaken in UK primary care, and will provide vital information about treatments to help the most vulnerable people in the ongoing fight against COVID-19.’

PANORAMIC will be from the departments Primary Care Clinical Trials Unit, while delivery of the trial will be supported by the NIHR Clinical Research Network and devolved administrations.

Professor Nick Lemoine, Medical Director of the NIHR Clinical Research Network said:

‘NIHR-supported research has already given the world some of the very first, life-saving COVID-19 treatments and vaccines. Antivirals represent the next important step in our effort to combat the virus, and with one of the most advanced health research sectors in the world, the UK is well-placed to take this challenge on.’



Contact our communications team

Opinions expressed are those of the authors and not of Oxford University. Readers' comments will be moderated - see our guidelines for further information.